The stock of HTG Molecular Diagnostics Inc (NASDAQ:HTGM) is a huge mover today! About 401,797 shares traded hands. HTG Molecular Diagnostics Inc (NASDAQ:HTGM) has risen 44.20% since March 11, 2016 and is uptrending. It has outperformed by 38.74% the S&P500.
The move comes after 5 months negative chart setup for the $21.84M company. It was reported on Oct, 14 by Barchart.com. We have $2.64 PT which if reached, will make NASDAQ:HTGM worth $2.40 million less.
Analysts await HTG Molecular Diagnostics Inc (NASDAQ:HTGM) to report earnings on November, 10.
HTG Molecular Diagnostics Inc (NASDAQ:HTGM) Ratings Coverage
Out of 2 analysts covering HTG Molecular Diagnostics (NASDAQ:HTGM), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. HTG Molecular Diagnostics has been the topic of 3 analyst reports since August 24, 2015 according to StockzIntelligence Inc. The rating was maintained by Canaccord Genuity with “Buy” on Tuesday, November 24. Rodman & Renshaw initiated it with “Buy” rating and $5 target price in Monday, August 22 report. As per Monday, August 24, the company rating was maintained by Canaccord Genuity.
According to Zacks Investment Research, “HTG Molecular Diagnostics, Inc. is engaged in developing and marketing a technology platform which consists of instrumentation, consumables and software analytics for sample profiling applications including tumor profiling, molecular diagnostic testing and biomarker development. Its products include HTG Edge System, HTG Edge Assays and HTG Assay Direct. HTG Molecular Diagnostics, Inc. is headquartered in Tucson, Arizona.”
More recent HTG Molecular Diagnostics Inc (NASDAQ:HTGM) news were published by: Nasdaq.com which released: “UPDATE â€“ HTG Molecular Diagnostics and Merck KGaA, Darmstadt, Germany, Enter …” on October 11, 2016. Also Quotes.Wsj.com published the news titled: “News HTG Molecular Diagnostics Inc.HTGM” on May 01, 2015. Globenewswire.com‘s news article titled: “Don Hardison Joins the Board of Directors for HTG Molecular Diagnostics” with publication date: May 03, 2016 was also an interesting one.
HTGM Company Profile
HTG Molecular Diagnostics, Inc., incorporated on December 14, 2000, is a commercial-stage firm that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development. The Company’s HTG Edge and HTG EdgeSeq platforms automate the molecular profiling of genes and gene activity using its nuclease protection chemistry on a range of biological samples. The Company’s HTG EdgeSeq chemistry, together with its HTG Edge or HTG EdgeSeq instrumentation and software, automates and adapts its nuclease protection chemistry to enable analysis using next generation sequencing (NGS) instrumentation. The HTG EdgeSeq system utilizes substantially the same sample preparation reagents as its original chemistry, but allows for read out on an NGS instrument.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.